History of an independent pharmaceutical company
DELBERT Pharma, a mission-driven company
Following on from DELBERT Pharma’s actions, becoming a misson-driven company gradually became an obvious choice.
The quality of a “mission-driven company” is an innovation introduced by the PACTE law (Plan d’Action pour la Croissance et la Transformation des Entreprises), enacted on May 22, 2019 in France, aimed at rethinking the role of companies in society. This quality represents a significant step forward for the integration of social and environmental issues into corporate strategy.
Defined in article L-210-10 of the French Commercial Code, it enables companies to voluntarily formalize social and/or environmental commitments in their bylaws, giving them a mission that reconciles the pursuit of profit with a contribution to the general interest.
By (re)placing social utility at the heart of their innovation process and their business and governance models, mission-driven companies also ensure long-term performance.
Implementing our mission is a journey towards achieving our statutory objectives. It is a path of continuous transformation, which requires integration into the day-to-day actions of all our teams, across the board and over the long term.
Eric Fidelin
Executive Vice-President, DELBERT Pharma
“From the outset, we have always been convinced of the importance of making a positive contribution to society through our pharmaceutical activities, in particular by putting patients left untreated at the heart of our concerns.
Over the years, we have invested significant resources in relocating production to Europe wherever possible. This investment helps reduce carbon emissions compared with drugs imported from Asia, and improves drug availability.
That’s why, in November 2023, we decided to become a Mission-driven company, and to include in our bylaws the following raison d’être, which is to act to maintain and develop medicines whose absence is detrimental to patients and to the balance of healthcare systems.
We are one of the few mission-driven pharmaceutical companies in France.
This approach, involving the commitment of all our teams and driven by our raison d’être and the statutory objectives we have set ourselves, federates them and raises the profile of the company beyond our walls”.
DELBERT Pharma
Our mission model
Acting to maintain and develop medicines whose absence is detrimental to patients and to the balance of healthcare systems
Developing a favourable ecosystem for essential medicines and refuse any loss of opportunity for patients.
Guarantee well-being, balance and quality of life at work
- entrepreneurial freedom through ideas and actions
- an environment of trust and respect
Integrate the collective challenge of environmental protection and contribute, alongside our partners, to reducing the ecological footprint of medicines.
Our history
A long-standing commitment to patients
2024
Laboratoires Delbert adopts the DELBERT Pharma trade name
Laboratoires DELBERT becomes DELBERT Pharma, a commercial brand serving the dynamic marketing of medicines under their own names and the operational implementation of the mission.
2023
DELBERT Pharma becomes a Mission-driven company
The “Mission-driven company” is enshrined in the company’s articles of association.
In response to a need expressed by healthcare professionals, DELBERT Pharma is marketing for the first time in France an injectable product for the treatment of anxiety and agitation.
2021
Development of the therapeutic arsenal linked to the central nervous system
Laboratoires Delbert has become a specialist in the prevention of relapses in bipolar disorders and intermittent schizoaffective states, and the curative treatment of manic or hypomanic states of excitation.
2020
Strengthening the portfolio
Laboratoires Delbert acquires the marketing authorization (MA) for a speciality used in the treatment of neuroleptic-induced parkinsonian syndromes.
In the same year, the company also acquired injectable forms, strengthening its antibiotics portfolio.
2018
Infectiology portfolio development
Laboratoires Delbert acquires the Marketing Authorization (MA) for an antibiotic used to treat various diseases linked to staphylococcal infection, and makes it available to healthcare professionals in France, Italy and the Czech Republic. They also acquire marketing authorization for a bronchial fluidifier, which they make available to patients in France.
2017
Supporting the therapeutic arsenal in infectiology
Laboratoires Delbert makes available to healthcare professionals an antibiotic used in the treatment of erysipelas (skin infection), syphilis and tropical infectious diseases. It is also used to prevent rheumatic fever and post-streptococcal glomerulonephritis (a specific form of inflammation of the kidney).
2016
Developing the therapeutic arsenal in psychiatry
Threatened with discontinuation, Laboratoires DELBERT acquired a range of products dedicated to certain mental disorders (schizophrenia, certain types of psychosis, etc.) and undertook to keep them in the psychiatric therapeutic arsenal.
2013
Birth of a start-up & launch of a new model for maintaining essential medicines for patients
Thierry HOFFMANN, an industrial pharmacist, and Marc CHILDS, a psychiatrist, acquire Laboratoires DELBERT with the aim of avoiding the short-term disappearance of essential medicines for patients. In a context of shortage of a specialty in the treatment of primary polyglobulia (Vaquez’s disease), they acquired a product. They quickly registered a new asset supplier, as well as a production site capable of handling highly toxic substances.
2002
Creation of Laboratoires DELBERT
Experts in regulatory affairs, Michel Berthier and his daughter founded Laboratoires DELBERT. The two pharmacists offer a regulatory activities service: over 300 marketing authorization dossiers for generic drugs have been registered in 10 years.
In 2002, Laboratoires DELBERT acquired its first pharmaceutical speciality and became a pharmaceutical establishment with operator status.
DELBERT Pharma
in figures
> 10
countries around the world benefiting from our products
+ 15
specialties brought back to market since 2013
> 60 %
of our products are MITMs (drugs of major therapeutic interest)
> 60%
of our products are made in France
> 90%
APIs from European companies
> 50%
of staff are doctors or pharmacists
> 90%
of our suppliers are European
> 90%
of employees are shareholders
+ 40 M€
turnover in 2023
REQUEST MEDICAL INFORMATION - REPORT AN ADVERSE EVENT
To request medical information on DELBERT Pharma products or report an adverse event,
please write to pharmacovigilance@delbert.fr or contact us on + 33 1 46 99 68 20